Entering text into the input field will update the search result below

iTeos climbs on agreement with GlaxoSmithKline for anti-TIGIT antibody

Jun. 14, 2021 7:22 AM ETGSK plc (GSK) Stock, ITOS StockGSK, ITOSBy: Dulan Lokuwithana, SA News Editor

Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration.
JuSun/iStock via Getty Images

  • iTeos Therapeutics (NASDAQ:ITOS) has surged ~60.2% in the pre-market after announcing an agreement with GlaxoSmithKline (NYSE:GSK) to jointly develop and commercialize EOS-448 an anti-TIGIT monoclonal antibody currently undergoing Phase 1 studies as a potential cancer therapy.
  • Per

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
GSK
--
ITOS
--